Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masoom Haider

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
European Radiology|February 2, 2010
Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillanceMartin E O'Malley, Peter Chung, Masoom Haider, et al.
European Radiology|July 4, 2024
Is MRI ready to replace biopsy during active surveillance?Adriano B Dias, Sungmin Woo, Riccardo Leni, et al.
Cancers|December 23, 2022
CT Radiomics and Whole Genome Sequencing in Patients with Pancreatic Ductal Adenocarcinoma: Predictive Radiogenomics ModelingRicarda Hinzpeter, Roshini Kulanthaivelu, Andres Kohan, et al.
The Journal of Urology|February 17, 2012
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort studyDavid Margel, Stanley A Yap, Nathan Lawrentschuk, et al.
Skeletal Radiology|July 1, 2022
T2-weighted MRI radiomics in high-grade intramedullary osteosarcoma: predictive accuracy in assessing histologic response to chemotherapy, overall survival, and disease-free survivalLawrence M White, Angela Atinga, Ali M Naraghi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 1, 2019
MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trialYasir Alayed, Laura D'Alimonte, Joelle Helou, et al.
The Journal of Urology|August 23, 2016
Evaluation of Focal Ablation of Magnetic Resonance Imaging Defined Prostate Cancer Using Magnetic Resonance Imaging Controlled Transurethral Ultrasound Therapy with Prostatectomy as the Reference StandardElizabeth Ramsay, Charles Mougenot, Robert Staruch, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2018
Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical TrialJure Murgic, Gerard Morton, Andrew Loblaw, et al.
Brachytherapy|May 26, 2019
Changes in ADC and T2-weighted MRI-derived radiomic features in patients treated with focal salvage HDR prostate brachytherapy for local recurrence after previous external-beam radiotherapySangjune Laurence Lee, Ananth Ravi, Gerard Morton, et al.
AJR. American Journal of Roentgenology|February 26, 2015
Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid)Kartik Jhaveri, Sean Cleary, Pascale Audet, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
European Radiology|February 2, 2010
Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillanceMartin E O'Malley, Peter Chung, Masoom Haider, et al.
European Radiology|July 4, 2024
Is MRI ready to replace biopsy during active surveillance?Adriano B Dias, Sungmin Woo, Riccardo Leni, et al.
Cancers|December 23, 2022
CT Radiomics and Whole Genome Sequencing in Patients with Pancreatic Ductal Adenocarcinoma: Predictive Radiogenomics ModelingRicarda Hinzpeter, Roshini Kulanthaivelu, Andres Kohan, et al.
The Journal of Urology|February 17, 2012
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort studyDavid Margel, Stanley A Yap, Nathan Lawrentschuk, et al.
Skeletal Radiology|July 1, 2022
T2-weighted MRI radiomics in high-grade intramedullary osteosarcoma: predictive accuracy in assessing histologic response to chemotherapy, overall survival, and disease-free survivalLawrence M White, Angela Atinga, Ali M Naraghi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 1, 2019
MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trialYasir Alayed, Laura D'Alimonte, Joelle Helou, et al.
The Journal of Urology|August 23, 2016
Evaluation of Focal Ablation of Magnetic Resonance Imaging Defined Prostate Cancer Using Magnetic Resonance Imaging Controlled Transurethral Ultrasound Therapy with Prostatectomy as the Reference StandardElizabeth Ramsay, Charles Mougenot, Robert Staruch, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2018
Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical TrialJure Murgic, Gerard Morton, Andrew Loblaw, et al.
Brachytherapy|May 26, 2019
Changes in ADC and T2-weighted MRI-derived radiomic features in patients treated with focal salvage HDR prostate brachytherapy for local recurrence after previous external-beam radiotherapySangjune Laurence Lee, Ananth Ravi, Gerard Morton, et al.
AJR. American Journal of Roentgenology|February 26, 2015
Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid)Kartik Jhaveri, Sean Cleary, Pascale Audet, et al.
Pageof 6